

+

J IIIIC

Combination therapy with oral contraceptive pills and antiandrogens especially for severe hirsutism causing emotional distress or no response to treatment with oral contraceptive pills.

Progestin generation	Progestin relative androgenicity	Progestin / dose	EE dose (mcg)
1	Medium	Norethindrone 0.5 - 1.0 mg	20/35
2	High	Levonorgestrel 0.15 mg	20/30
2 - 3	Low	Norgestimate 0.25 mg	35
3	Low	Gestodene 0.075 mg	20/30
3	Low	Desogestrel 0.15 mg	20/30
4	Antiandrogen	DSP 3 mg	20/30
-	Antiandrogen	CPA 2 mg	35

Antiandrogens	Dosing	
Spironolactone	100 - 200 mg/d (given in divided doses twice daily)	
Finasteride	2.5 - 5 mg/d	
Flutamide	250 - 500 mg/d (high dose), 62.5 ≤ 250 mg/d (low dose)	

References: 1. H.F. Escobar-Morreale, E. Carmina, D. Dewailly, A. Gambineri, *et al.* Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. *Human Reproduction Update.* Volume 18, Issue 2, March/April 2012, Pages 146–170, https://doi.org/10.1093/humupd/dmr042 2. Akter N, Qureshi NK. Hirsutism - Evaluation and Treatment. *Delta Med Col J.* 2016; 4(1):35–44.

Sources: 1. Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1233-1257. doi: 10.1210/jc.2018-00241. PMID: 29522147.
Sachdeva S. Hirsutism: Evaluation and treatment. Indian J Dermatol. 2010; 55(1): 3–7. 3. Kini S, Ramalingam M. Hirsutism, Obstetrics, Gynaecology and Reproductive Medicine (2018), https://doi.org/10.1016/j.ogrn.2018.03.004.

*Hirsutism may be outside the health authority approved indication for oral combined estrogen progestin combinations in India **Disclaimer:** This algorithm poster is for informational purpose only and by no means obligates or influences any medical practitioners to prescribe, recommend or purchase any products from Bayer Zydus Pharma Private Limited (Bayer) or any of its affiliates. Please read full prescribing information before issuing prescription for the product mentioned in this poster. The information contained herein should not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for the product referenced. Although great care has been taken in compiling the information or for any errors, omissions or inaccuracies in this publications whether arising from negligence or otherwise howsoever, or for any consequences arising therefrom. Strictly for the use of registered medical practitioner or hospital or laboratory only.



